Novartis Ag (NVS) Receivables - Net (2009 - 2025)

Novartis Ag (NVS) has 14 years of Receivables - Net data on file, last reported at $8.9 billion in Q4 2025.

• Quarterly Receivables - Net rose 20.4% year-over-year to $8.9 billion in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $8.9 billion (up 20.4% YoY) and the FY2025 annual result came in at $8.9 billion, up 20.4% from the prior year.
• Receivables - Net retreated to $8.9 billion in Q4 2025 per NVS's latest filing, from $9.1 billion in the prior quarter.
• The five-year high for Receivables - Net was $9.2 billion in Q2 2023, with the low at $7.1 billion in Q4 2023.
• Average Receivables - Net over 5 years is $8.3 billion, with a median of $8.3 billion recorded in 2021.
• Year-over-year, Receivables - Net decreased 11.89% in 2023 and advanced 20.4% in 2025.
• Novartis Ag's Receivables - Net stood at $8.0 billion in 2021, then gained by 0.76% to $8.1 billion in 2022, then fell by 11.89% to $7.1 billion in 2023, then increased by 4.45% to $7.4 billion in 2024, then advanced by 20.4% to $8.9 billion in 2025.
• Business Quant data shows NVS's Receivables - Net at $8.9 billion in Q4 2025, $9.1 billion in Q2 2025, and $7.4 billion in Q4 2024.